Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Am J Trop Med Hyg ; 102(2): 268-273, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31872796

RESUMEN

In immunocompromised patients, visceral leishmaniasis (VL) can present with atypical clinical symptoms that include poor response to treatment. No optimal therapeutic regimen is available for such cases. In a splenectomized male patient, we observed a disseminated form of the disease in the liver, bone marrow, lymph nodes, and gastrointestinal tract. There was an apparent clinical improvement when he was initially treated with liposomal amphotericin B (L-AmB), but this was followed by a relapse involving severe clinical symptoms. He was finally treated successfully with a combination of L-AmB, meglumine antimoniate, and pentamidine isethionate. It is important to include asplenia as an immunosuppressive condition that induces exotic VL pathologies. In such cases, combination anti-Leishmania drug therapy should be considered.


Asunto(s)
Anfotericina B/uso terapéutico , Leishmaniasis Visceral/tratamiento farmacológico , Antimoniato de Meglumina/uso terapéutico , Pentamidina/uso terapéutico , Esplenectomía , Anfotericina B/administración & dosificación , Antiprotozoarios/administración & dosificación , Antiprotozoarios/uso terapéutico , Médula Ósea/parasitología , Quimioterapia Combinada , Humanos , Huésped Inmunocomprometido , Mucosa Intestinal/parasitología , Leishmaniasis Visceral/inmunología , Ganglios Linfáticos/parasitología , Masculino , Antimoniato de Meglumina/administración & dosificación , Persona de Mediana Edad , Pentamidina/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA